Postnatal AVP treatments prevent social deficit in adolescence of valproic acid-induced rat autism model
Copyright © 2021 Elsevier Inc. All rights reserved..
Studies have shown that arginine-vasopressin (AVP) is an important neuropeptide regulating social behaviors. The present work aimed to detect changes in the AVP numbers and level in a valproic acid (VPA)-induced rat model of autism and the underlying mechanism of its pathogenesis. Our results indicated that infants exposed to VPA showed obviously impaired communication and repetitive behaviors with reduced number of AVP-ir cells in paraventricular nucleus (PVN) and cerebrospinal fluid (CSF). The postnatal subcutaneous injection of AVP can alleviate social preference deficits and stereotyped behaviors, accompanied with the increase of the AVP concentrations in the CSF. We concluded that AVP system was involved in etiology of VPA-induced autism-like symptoms and postnatal AVP treatment rescued the behavioral deficits,which could be a promising treatment for autism.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
---|---|
Enthalten in: |
Peptides - 137(2021) vom: 01. März, Seite 170493 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wu, Jing [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.12.2021 Date Revised 27.12.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.peptides.2021.170493 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31986166X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM31986166X | ||
003 | DE-627 | ||
005 | 20231225172344.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.peptides.2021.170493 |2 doi | |
028 | 5 | 2 | |a pubmed24n1066.xml |
035 | |a (DE-627)NLM31986166X | ||
035 | |a (NLM)33422647 | ||
035 | |a (PII)S0196-9781(21)00001-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wu, Jing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Postnatal AVP treatments prevent social deficit in adolescence of valproic acid-induced rat autism model |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.12.2021 | ||
500 | |a Date Revised 27.12.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
520 | |a Studies have shown that arginine-vasopressin (AVP) is an important neuropeptide regulating social behaviors. The present work aimed to detect changes in the AVP numbers and level in a valproic acid (VPA)-induced rat model of autism and the underlying mechanism of its pathogenesis. Our results indicated that infants exposed to VPA showed obviously impaired communication and repetitive behaviors with reduced number of AVP-ir cells in paraventricular nucleus (PVN) and cerebrospinal fluid (CSF). The postnatal subcutaneous injection of AVP can alleviate social preference deficits and stereotyped behaviors, accompanied with the increase of the AVP concentrations in the CSF. We concluded that AVP system was involved in etiology of VPA-induced autism-like symptoms and postnatal AVP treatment rescued the behavioral deficits,which could be a promising treatment for autism | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a AVP therapy | |
650 | 4 | |a AVP-ir neuron numbers | |
650 | 4 | |a Autism spectrum disorder | |
650 | 4 | |a Autism-like behavior | |
650 | 7 | |a AVP protein, human |2 NLM | |
650 | 7 | |a Neurophysins |2 NLM | |
650 | 7 | |a Protein Precursors |2 NLM | |
650 | 7 | |a Vasopressins |2 NLM | |
650 | 7 | |a 11000-17-2 |2 NLM | |
650 | 7 | |a Arginine Vasopressin |2 NLM | |
650 | 7 | |a 113-79-1 |2 NLM | |
650 | 7 | |a Valproic Acid |2 NLM | |
650 | 7 | |a 614OI1Z5WI |2 NLM | |
700 | 1 | |a Dai, Yu-Chuan |e verfasserin |4 aut | |
700 | 1 | |a Lan, Xing-Yu |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Hong-Feng |e verfasserin |4 aut | |
700 | 1 | |a Bai, Shu-Zhen |e verfasserin |4 aut | |
700 | 1 | |a Hu, Ying |e verfasserin |4 aut | |
700 | 1 | |a Han, Song-Ping |e verfasserin |4 aut | |
700 | 1 | |a Han, Ji-Sheng |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Rong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Peptides |d 1985 |g 137(2021) vom: 01. März, Seite 170493 |w (DE-627)NLM012597023 |x 1873-5169 |7 nnns |
773 | 1 | 8 | |g volume:137 |g year:2021 |g day:01 |g month:03 |g pages:170493 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.peptides.2021.170493 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 137 |j 2021 |b 01 |c 03 |h 170493 |